This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in overweight/obesity
Timeframe: At baseline, 3 months, 6 months and 12 months
Change in sarcopenia
Timeframe: At baseline and 6 months
Change in slowness
Timeframe: At baseline, 3 months and 6 months
Change in weakness
Timeframe: At baseline, 3 months, and 6 months
Change in inactivity
Timeframe: At baseline, 3 months, 6 months, and 12 months
Change in fatigue
Timeframe: At baseline, 3 months, 6 months, and 12 months